ENOV on NYSE

Colfax Corporation

American medical technology company

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1995Founded1

Compare with MSA Safety, Align Technology or Bone Biologics Corp, or pick any stock.

  • TickerENOV on NYSE1
  • Industrymedical technology1
  • HeadquartersAnnapolis Junction1
  • Websitewww.colfaxcorp.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address2900 Lake Vista Drive, Suite 200, Lewisville, Tx 750675
  • Filer categoryLarge accelerated filer5
  • LEI635400OP2DYYYMOIYL174
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressCORPORATION TRUST CENTER, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 28637694

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Dallas, Texas and is listed on the NYSE as ENOV. The company has over 8,000 employees operating at 30 sites around the world.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

59.8%Gross margin8
-50.0%Operating margin8
-52.7%Net margin8
6.7%Revenue growth, 20258
-79.5%Return on equity8
0.85×Debt to equity8
$19.9MFree cash flow8

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue40¢$902.8M
  • Research and development5¢$120.3M
  • Selling, general and admin48¢$1.1B
  • Other costs4¢$97.7M
  • Interest2¢$34.8M
  • Income tax1¢$22.3M

Out of $2.2B in revenue.8 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending91¢$197.4M
  • Share buybacks2¢$3.5M
  • Kept or used elsewhere8¢$16.4M

Out of $217.3M of cash from operations.8

Financial statements

Revenue91011128$2.2B in 2025−32% since 2019
0$1.0B$2.0B$3.0B$4.0B2019: $3.3B$3.3B20192020: $1.1B$1.1B2020−66%2021: $1.4B$1.4B2021+27%2022: $1.6B$1.6B2022+10%2023: $1.7B$1.7B2023+9%2024: $2.1B$2.1B2024+23%2025: $2.2B$2.2B2025+7%
Gross profit91011128$1.3B in 2025−4% since 2019
0$500.0M$1.0B$1.5B2019: $1.4B$1.4B20192020: $603.6M$603.6M2020−57%2021: $777.7M$777.7M2021+29%2022: $869.4M$869.4M2022+12%2023: $990.8M$990.8M2023+14%2024: $1.2B$1.2B2024+19%2025: $1.3B$1.3B2025+14%
Operating income91011128-$1.1B in 2025
-$1.5B-$1.0B-$500.0M0$500.0M2019: $203.6M$203.6M20192020: -$66.2M-$66.2M20202021: -$62.8M-$62.8M2021−5%2022: -$71.2M-$71.2M2022+13%2023: -$65.7M-$65.7M2023−8%2024: -$775.7M-$775.7M2024+1081%2025: -$1.1B-$1.1B2025+45%
Net income91011128-$1.2B in 2025+124% since 2019
-$1.5B-$1.0B-$500.0M0$500.0M2019: -$527.6M-$527.6M20192020: $42.6M$42.6M20202021: $71.7M$71.7M2021+68%2022: -$13.3M-$13.3M20222023: -$33.3M-$33.3M2023+150%2024: -$825.5M-$825.5M2024+2382%2025: -$1.2B-$1.2B2025+43%
Fiscal year2019202020212022202320242025
Revenue$3.3B9$1.1B10$1.4B11$1.6B12$1.7B8$2.1B8$2.2B8
Cost of revenue$1.9B9$517.1M10$648.5M11$693.7M12$716.4M8$926.9M8$902.8M8
Gross profit$1.4B9$603.6M10$777.7M11$869.4M12$990.8M8$1.2B8$1.3B8
Research and development$34.3M10$49.1M11$60.8M12$75.3M8$91.3M8$120.3M8
Selling, general and admin$1.1B9$515.5M10$665.8M11$772.9M12$830.3M8$1.0B8$1.1B8
Operating income$203.6M9-$66.2M10-$62.8M11-$71.2M12-$65.7M8-$775.7M8-$1.1B8
Interest$119.5M9$52.8M10$29.1M11$24.1M12$19.7M8$57.1M8$34.8M8
Income before tax-$121.8M11-$2.1M12-$67.1M8-$822.9M8-$1.2B8
Income tax$31.6M9-$44.6M10-$19.5M11$36.1M12-$13.3M8$4.5M8$22.3M8
Net income-$527.6M9$42.6M10$71.7M11-$13.3M12-$33.3M8-$825.5M8-$1.2B8
Earnings per share-$3.899$0.9310$1.4011-$0.2512-$0.618-$14.938-$20.758
Earnings per share (diluted)-$3.899$0.9310$1.4011-$0.2512-$0.618-$14.938-$20.758
Shares (weighted, basic)51.1M shares1154.1M shares1254.5M shares855.3M shares857.1M shares8
Shares (weighted, diluted)51.1M shares1154.1M shares1254.5M shares855.3M shares857.1M shares8

Compare Colfax Corporation with another company

The story

Founded by Mitchell Rales in 1995.1

The company was founded in 1995 as the Colfax Corporation in Richmond, Virginia, by brothers Steven and Mitchell Rales. In August 1997, Colfax acquired approximately 93% of IMO's common stock through a public tender offer. At the time of the acquisition, IMO was a diversified industrial manufacturer, with $469.0 million in annual revenue and five business units: Boston Gear, IMO Pump, Morse Controls, Gems Sensors, and Roltra Morse. Simultaneously with the closing of the tender offer, IMO divested its Gems Sensors and Roltra Morse units to narrow the strategic focus to power transmission and fluid handling.

In January 2012, Colfax completed the acquisition of Charter International, successor to the British South Africa Company, and the parent company of ESAB (welding and cutting) and Howden (air and gas handling products), for $2.4 billion. More than 25 acquisitions were completed from 2012–2019 to build-out the three industrial businesses, fluid handling, fabrication technologies (ESAB), and air & gas handling (Howden).

In December 2017, Colfax sold its original fluid handling platform to Circor International for cash and stock with a total estimated aggregate consideration of $860 million. In November 2018, Colfax expanded into the medical device space by acquiring DJO Global from The Blackstone Group for $3.15bn. In May 2019, KPS Capital Partners (KPS) announced that it has signed an agreement to acquire Howden Turbo from Colfax Corporation for $1.8bn.

In March 2021, Colfax announced that it would spin off its ESAB industrial business in a tax-efficient manner and pursue a focused medical technologies strategy. This spin-off was completed in April 2022, following which ESAB became an independent public company and Colfax was renamed Enovis. The spin-off was the final action taken to transform the portfolio of businesses from purely industrial to medical technologies. These actions included divesting the fluid handling and air and gas handling businesses in 2017 and 2019, respectively, and acquiring DJO Global in 2019. Additional acquisitions were made, and Colfax went public with an initial public offering in May 2008 as a fluid handling company. The headquarters were subsequently moved to Annapolis Junction, Maryland.

In September 2023, Enovis announced that it had reached a definitive agreement to acquire the Villanova di San Daniele del Friuli-headquartered medical device company LimaCorporate for approximately €800 million. On January 3, 2024, it was reported that the purchase of LimaCorporate had been completed.

From Wikipedia’s article on Enovis, shared under CC BY-SA 4.0.6

Leadership

Who has led Colfax Corporation, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (46)

Subsidiaries and ownership

Subsidiaries

Also consolidated

From Wikidata.1 Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.

Acquisitions

  1. 2015Acquired Roots Blowers1

Former names

  • Colfax CORPJan 4, 2008 to Mar 18, 20225

Timeline

  1. May 13, 2025New chief executive Damien McDonald becomes CEO16
  2. Feb 27, 2019New chief executive Brady Shirley becomes CEO17
  3. Jul 27, 2015New chief executive Matthew L. Trerotola becomes CEO18
  4. Jul 28, 2014New chief executive Darryl Mayhorn becomes CEO19
  5. Apr 24, 2012New chief executive Steve Simms becomes CEO21
  6. Feb 24, 2012New chief executive Ian Brander becomes CEO20
  7. Jan 12, 2010New chief executive Clay Kiefaber becomes CEO22
  8. 1995Founded Founded1

Filings

451 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 289 insider forms, 41 large holders, 40 other. The latest 20:

  1. Oct 1, 20264 EDGAR
  2. Sep 8, 20264 EDGAR
  3. Sep 4, 20264 EDGAR
  4. Sep 4, 20264 EDGAR
  5. Sep 1, 20268-K EDGAR
  6. Aug 14, 2026SCHEDULE 13G EDGAR
  7. Aug 6, 202610-Q EDGAR
  8. Aug 6, 20268-K EDGAR
  9. Jul 28, 2026SCHEDULE 13G/A EDGAR
  10. Jul 8, 2026SCHEDULE 13G/A EDGAR
  11. Jul 1, 20264 EDGAR
  12. Jun 26, 202611-K EDGAR
  13. Jun 16, 20264 EDGAR
  14. Jun 16, 20264/A EDGAR
  15. Jun 15, 20264 EDGAR
  16. Jun 11, 20264 EDGAR
  17. Jun 3, 20264 EDGAR
  18. May 28, 2026SD EDGAR
  19. May 21, 20264 EDGAR
  20. May 21, 20264 EDGAR

The 451 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

93 open-market trades by officers, directors and large owners since October 2021: 20 buys and 73 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 4, 2026Engert OliverChief Administrative OfficerBuy2,660$18.80$50.0KForm 4
Sep 4, 2026McDonald DamienChief Executive OfficerBuy13,035$19.15$249.6KForm 4
Sep 3, 2026Engert OliverChief Administrative OfficerBuy5,140$19.46$100.0KForm 4
Sep 2, 2026Engert OliverChief Administrative OfficerBuy2,458$20.32$49.9KForm 4
Jun 15, 2026Engert OliverChief Administrative OfficerBuy1,000$20.92$20.9KForm 4
Jun 11, 2026Engert OliverChief Administrative OfficerBuy1,200$21.62$25.9KForm 4
Jun 10, 2026Engert OliverChief Administrative OfficerBuy1,000$23.00$23.0KForm 4
Jun 1, 2026Engert OliverChief Administrative OfficerBuy1,000$22.22$22.2KForm 4
Mar 13, 2026Engert OliverChief Administrative OfficerBuy1,000$23.74$23.7KForm 4
Mar 10, 2026Engert OliverChief Administrative OfficerBuy1,000$23.93$23.9KForm 4
Mar 9, 2026Engert OliverChief Administrative OfficerBuy1,000$23.39$23.4KForm 4
Mar 6, 2026Engert OliverChief Administrative OfficerBuy750$24.41$18.3KForm 4
Mar 4, 2026Engert OliverChief Administrative OfficerBuy250$25.10$6.3KForm 4
Mar 3, 2026Engert OliverChief Administrative OfficerBuy1,000$24.77$24.8KForm 4
Feb 27, 2026Engert OliverChief Administrative OfficerBuy1,000$25.50$25.5KForm 4
Dec 9, 2025PRYOR DANIEL ASale1,665$27.21$45.3KForm 4
Nov 25, 2025KLECKNER JOHNPrincipal Accounting OfficerBuy2,468$30.32$74.8KForm 4
Sep 11, 2025McDonald DamienChief Executive OfficerBuy6,457$30.97$200.0KForm 4
Aug 22, 2025Tandy Bradley JSVP and Chief Legal OfficerBuy3,200$31.41$100.5KForm 4
Aug 20, 2025BERRY PHILLIP BENJAMIN (BEN)SVP, Chief Financial OfficerBuy2,500$29.71$74.3KForm 4

All 93 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88